Checkpoint Therapeutics Inc. (CKPT) has secured FDA approval for its lead asset Cosibelimab for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Cutaneous squamous cell carcinoma, the second most common type of skin cancer in the United States, is estimated to affect around 1.8 million individuals each year, according to the Skin Cancer Foundation. The U.S. cSCC market opportunity is valued at over $1 billion.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com